Noridian opens three proposed MolDX policies for comments through October 11
Oct 11, 2026 edition · GC-2026-0033 · Published 2026-10-11 · Version 3 · Proposed
Noridian's three MolDX proposals remain open for comments through October 11. The notice concerns specified Jurisdiction E Part B contracts and supplies a consultation route, rather than operative coverage criteria.
What happened
The August 31 notice lists DL40435 for renal-carcinoma transcriptional biomarkers, DL40427 for NGS in hematologic malignancies, and DL40411 for genome-wide detection of copy-number alterations and structural variants in hematologic neoplasms. Its comment period runs August 27 through October 11.
The listed contracts cover northern/southern California, Nevada, and specified Pacific jurisdictions. Noridian directs commenters to identify the specific policy and consult its submission instructions. The notice itself does not finalize these drafts or establish their detailed clinical criteria.
Scope and timing
- Authority status
- Proposed
- Applicability
- Potentially applicable
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, California, Hawaii, Nevada
- Affected functions
- Coding, Clinical Operations, Revenue Cycle, Compliance
- Responsible owner
- Coding
- Recorded date
- 2026-10-11
- Date type
- comment
Why it matters
Affected laboratories and ordering services can review proposed coverage criteria before finalization. Publication for comment does not create a final coverage policy or a current billing change.
Recommended action
Coding and laboratory leaders should review the three proposed LCDs, assess their test menus, and decide whether to submit evidence-based comments by October 11. Keep this proposal separate from the finalized October MolDX changes.
Sources
- Multiple MolDX proposed LCDs published for review and commentsOfficial · Noridian, Jurisdiction E · 2026-08-31 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Medicare & Medicaid report →